stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) EPS (diluted)
Scholar Rock Holding Corporation's EPS (diluted) for fiscal 2025 was −$3.29, compared with −$2.47 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$3.32. Over the past ten years it has ranged from −$15.30 (fiscal 2017) to −$1.85 (fiscal 2019); the current reading is higher than 40% of that period. Scholar Rock Holding Corporation ranks 390th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.29 | — |
| FY2024 | −$2.47 | — |
| FY2023 | −$1.99 | — |
| FY2022 | −$2.26 | — |
| FY2021 | −$3.59 | — |
| FY2020 | −$2.81 | — |
| FY2019 | −$1.85 | — |
| FY2018 | −$3.15 | — |
| FY2017 | −$15.30 | — |
| FY2016 | −$10.11 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.84 | — |
| Mar 2026 | −$0.83 | — |
| Dec 2025 | −$0.75 | — |
| Sep 2025 | −$0.90 | — |
| 32 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ERAS Erasca, Inc. compare | −$0.95 |
| PTCT PTC Therapeutics, Inc. compare | −$1.40 |
| COGT Cogent Biosciences, Inc. compare | −$2.16 |
| CGON CG Oncology, Inc. compare | −$2.69 |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$2.73 |
| IMVT Immunovant, Inc. compare | −$2.82 |
| SRRK Scholar Rock Holding Corporation | −$3.32 |
| KOD Kodiak Sciences Inc. compare | −$4.19 |
| MANE Veradermics Incorporated compare | −$45.88 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SRRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement